{"id":2918,"date":"2020-06-04T07:46:03","date_gmt":"2020-06-04T07:46:03","guid":{"rendered":"http:\/\/novalab.bold-themes.com\/demo-02\/?page_id=2918"},"modified":"2026-02-09T13:21:01","modified_gmt":"2026-02-09T12:21:01","slug":"partner","status":"publish","type":"page","link":"https:\/\/impact-acmproject.eu\/sk\/partner\/","title":{"rendered":"Partner"},"content":{"rendered":"

<\/div><\/div>
<\/div>

PARTNER<\/span><\/span><\/h1>
Partner projektu<\/div><\/header>
<\/div><\/div><\/div><\/div>
<\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>
\"bt_bb_sekcia_bottom_sekcia_krytie_image\"<\/div><\/section>
\"https:\/\/impact-acmproject.eu\/wp-content\/uploads\/2023\/11\/universita_padova.webp\"<\/span><\/div>
<\/div><\/div><\/div><\/div>

Universit\u00e0 degli Studi di Padova<\/span><\/span><\/h3><\/header>
<\/div>
<\/div>
<\/p>\n

Katedra biol\u00f3gie Univerzity v Padove bola zalo\u017een\u00e1 v okt\u00f3bri 1983 zl\u00fa\u010den\u00edm \u00fastavov \u017eivo\u010d\u00ed\u0161nej biol\u00f3gie, botaniky a antropol\u00f3gie spolu s Botanickou z\u00e1hradou Padova a morskou biologickou stanicou Chioggia (Ben\u00e1tky).<\/p>\n

UNIDP ako koordin\u00e1tor projektu zabezpe\u010duje s\u00falad cie\u013eov projektu s podmienkami dohody o grante a dohody o konzorciu. Jeho \u00falohou je zv\u00fd\u0161i\u0165 stratifik\u00e1ciu pacientov s ACM, ur\u010di\u0165 pr\u00ednos variantov nezn\u00e1meho v\u00fdznamu a vyvin\u00fa\u0165 a charakterizova\u0165 pr\u00edslu\u0161n\u00e9 predklinick\u00e9 modely. Okrem toho nesie zodpovednos\u0165 za identifik\u00e1ciu potenci\u00e1lnych etick\u00fdch probl\u00e9mov a ich rie\u0161enie. UNIPD takisto \u00fazko spolupracuje s partnermi s cie\u013eom pos\u00fadi\u0165 o\u010dak\u00e1van\u00e9 etick\u00e9 obavy a rie\u0161i\u0165 tie, ktor\u00e9 sa objavili po\u010das priebehu projektu.<\/p>\n

\n<\/div>

<\/div>
webov\u00e1 str\u00e1nka<\/span><\/a><\/div>
<\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>
<\/div><\/div><\/div><\/div><\/div><\/div>

Consorzio Italbiotec<\/span><\/span><\/h3><\/header>
<\/div>
<\/div>
<\/p>\n

Ved\u00faca talianska neziskov\u00e1 organiz\u00e1cia v biotechnologickom sektore. Vedie vedeck\u00fd v\u00fdvoj a \u00fa\u010dinn\u00fd prenos poznatkov medzi v\u00fdskumnou komunitou a priemyslom k formovaniu \u0161pi\u010dkov\u00e9ho inova\u010dn\u00e9ho ekosyst\u00e9mu poh\u00e1\u0148an\u00e9ho biotechnologick\u00fdmi startupmi, spolo\u010dnos\u0165ami a univerzitami, kde spolupr\u00e1ca a v\u00fdmena poznatkov podnecuj\u00fa rast a udr\u017eate\u013en\u00fa inov\u00e1ciu. Zdru\u017eenie Consorzio Italbiotec bude v\u010faka svojim odborn\u00fdm znalostiam zodpovedn\u00e9 za \u010dinnosti \u0161\u00edrenia, komunik\u00e1cie, odbornej pr\u00edpravy a vyu\u017e\u00edvania s cie\u013eom na vysokej \u00farovni budova\u0165 a udr\u017eiava\u0165 siln\u00fa a \u00fa\u010dinn\u00fa komunika\u010dn\u00fa kult\u00faru v r\u00e1mci projektu. Strat\u00e9giou sa podpor\u00ed aj informovan\u00e1 komunita zainteresovan\u00fdch str\u00e1n a viacer\u00fdch akt\u00e9rov, ktor\u00ed sa zauj\u00edmaj\u00fa o predmet IMPACT a s\u00fa mu oddan\u00ed, a prispeje sa k optim\u00e1lnemu vyu\u017e\u00edvaniu jeho inova\u010dn\u00fdch v\u00fdsledkov.<\/p>\n

\n<\/div>

<\/div>
webov\u00e1 str\u00e1nka<\/span><\/a><\/div>
<\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>
<\/div>
\"https:\/\/impact-acmproject.eu\/wp-content\/uploads\/2023\/11\/italbiotec.webp\"<\/span><\/div><\/div><\/div><\/div><\/div><\/div>
<\/div><\/div><\/div><\/div><\/div><\/div>
\"https:\/\/impact-acmproject.eu\/wp-content\/uploads\/2023\/11\/maastricht.webp\"<\/span><\/div>
<\/div><\/div><\/div><\/div>

Maastrichtskej univerzite<\/span><\/span><\/h3><\/header>
<\/div>
<\/div>
<\/p>\n

School for Cardiovascular Diseases (CARIM) v Maastrichtskej univerzite je celosvetov\u00fdm referen\u010dn\u00fdm centrom pre \u0161t\u00fadium g\u00e9nov\u00fdch regula\u010dn\u00fdch mechanizmov pri kontrole genetick\u00fdch a z\u00edskan\u00fdch foriem srdcov\u00e9ho zlyhania. Modely in vivo a \u013eudsk\u00e9 modely in vitro sa be\u017ene pou\u017e\u00edvaj\u00fa na \u0161t\u00fadium \u013eudsk\u00fdch srdcov\u00fdch ochoren\u00ed uplat\u0148ovan\u00edm molekul\u00e1rnych a bunkov\u00fdch biologick\u00fdch pr\u00edstupov, ako aj vysokov\u00fdkonn\u00fdch zariaden\u00ed na genetick\u00fd skr\u00edning, technol\u00f3gie vyra\u010fovania transg\u00e9nov\/g\u00e9nov, fenotypiz\u00e1cie srdca a zobrazovac\u00edch techn\u00edk. U\u017e nieko\u013eko rokov poskytuje kompletn\u00fd a glob\u00e1lny medzn\u00edk pre profilovanie mikroRNA v srdcovom zlyhan\u00ed, t\u00e1to in\u0161tit\u00facia je pova\u017eovan\u00e1 za l\u00eddra v epigenetickej oblasti srdca na celom svete.<\/p>\n

\n<\/div>

<\/div>
webov\u00e1 str\u00e1nka<\/span><\/a><\/div>
<\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>
<\/div><\/div><\/div><\/div><\/div><\/div>

AccelBio<\/span><\/span><\/h3><\/header>
<\/div>
<\/div>
<\/p>\n

AccelBio je portugalsk\u00e1 neziskov\u00e1 R&D biotechnologick\u00e1 organiz\u00e1cia zdru\u017euj\u00faca partnerov z farmaceutick\u00e9ho, biotechnologick\u00e9ho, akademick\u00e9ho, rizikov\u00e9ho kapit\u00e1lu a biotechnologick\u00e9ho parku.<\/p>\n

AccelBio vyu\u017e\u00edva nov\u00e9 racion\u00e1lne pr\u00edstupy na podporu transla\u010dn\u00fdch projektov objavovania liekov v predklinick\u00fdch f\u00e1zach od akademickej obce a startupov. Medzi ich odborn\u00e9 oblasti patria okrem in\u00e9ho kardiovaskul\u00e1rne a neurologick\u00e9 ochorenia, imunol\u00f3gia, z\u00e1pal, infekcia, onkol\u00f3gia a nefrol\u00f3gia.<\/p>\n

Na podporu v\u00fdvoja liekov AccelBio hos\u0165uje technologick\u00e9 platformy vr\u00e1tane pokro\u010dil\u00fdch organoidov, multiomiky, v\u00fdpo\u010dtovej biol\u00f3gie, bioinformatiky a vysokov\u00fdkonn\u00e9ho skr\u00edningu. Transla\u010dn\u00fd t\u00edm je tie\u017e ur\u010den\u00fd na podporu v\u00fdskumn\u00fdch pracovn\u00edkov a podnikate\u013eov pri navrhovan\u00ed pl\u00e1nu na uvedenie na trh, ktor\u00fd sa riadi najlep\u0161\u00edmi postupmi v danom odvetv\u00ed a vedie k vysokokvalitn\u00fdm kandid\u00e1tom na lieky.<\/p>\n

V r\u00e1mci IMPACT bude Accelbio pou\u017e\u00edva\u0165 svoje unik\u00e1tne pokro\u010dil\u00e9 \u013eudsk\u00e9 srdcov\u00e9 organoidy na podporu stratifik\u00e1cie pacientov s ACM a odhalenie a valid\u00e1ciu nov\u00fdch mechanizmov \u00fa\u010dinku, biomarkerov a terapeutick\u00fdch cie\u013eov pre t\u00fato chorobu.<\/p>\n

\n<\/div>

<\/div>
webov\u00e1 str\u00e1nka<\/span><\/a><\/div>
<\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>
<\/div>
\"logo<\/span><\/div><\/div><\/div><\/div><\/div><\/div>
<\/div><\/div><\/div><\/div><\/div><\/div>
\"https:\/\/impact-acmproject.eu\/wp-content\/uploads\/2023\/11\/italfarmaco.webp\"<\/span><\/div>
<\/div><\/div><\/div><\/div>

K\u00fape\u013en\u00e9 stredisk\u00e1 - Italfarmaco (ITF)<\/span><\/span><\/h3><\/header>
<\/div>
<\/div>
<\/p>\n

Italfarmaco SpA je talianska nadn\u00e1rodn\u00e1 spolo\u010dnos\u0165 v s\u00fakromnom vlastn\u00edctve so s\u00eddlom v Mil\u00e1ne. P\u00f4sob\u00ed v Taliansku a v zahrani\u010d\u00ed vo farmaceutickom a chemicko-farmaceutickom sektore prostredn\u00edctvom spolo\u010dnost\u00ed, v ktor\u00fdch m\u00e1 priamy alebo nepriamy z\u00e1ujem. Spolo\u010dnos\u0165 Italfarmaco bola zalo\u017een\u00e1 v roku 1938. Skupina m\u00e1 modern\u00e9 priemyseln\u00e9 zariadenia na v\u00fdrobu vysoko kvalitn\u00fdch farmaceutick\u00fdch v\u00fdrobkov a m\u00e1 siln\u00fd z\u00e1v\u00e4zok k v\u00fdskumu, najm\u00e4 v kardiovaskul\u00e1rnej, imunologickej a onkologickej oblasti.
\nV r\u00e1mci IMPACT bude ITF zodpovedn\u00e1 za v\u00fdvoj liekov a skr\u00edningov\u00e9 testy liekov a bude pracova\u0165 na identifik\u00e1cii nov\u00fdch chemotypov podobn\u00fdch liekom s po\u017eadovan\u00fdm profilom.<\/p>\n

\n<\/div>

<\/div>
webov\u00e1 str\u00e1nka<\/span><\/a><\/div>
<\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>
<\/div><\/div><\/div><\/div><\/div><\/div>

UMC Utrecht<\/span><\/span><\/h3><\/header>
<\/div>
<\/div>
<\/p>\n

University Medical Center Utrecht (UMC Utrecht) je n\u00e1rodne a medzin\u00e1rodne
\nuzn\u00e1van\u00e9 odborn\u00e9 centrum pre dedi\u010dn\u00e9 srdcov\u00e9 choroby. Nach\u00e1dza sa tu ve\u013ek\u00e1 biobanka
\nkrv a tkanivo (biopsia, pitva, transplant\u00e1cia) pacientov s kardiomyopatiou. UMC
\nUtrecht sl\u00fa\u017ei ako n\u00e1rodn\u00e9 referen\u010dn\u00e9 centrum pre pacientov s arytmiou
\nkardiomyopatia (ACM) a koordinuje n\u00e1rodn\u00fd register pacientov s ACM (
\nHolandsk\u00fd register ACM), ktor\u00fd v s\u00fa\u010dasnosti zah\u0155\u0148a > 2000 pacientov s ACM a
\npr\u00edbuzn\u00fdch.<\/p>\n

V r\u00e1mci IMPACT, UMC Utrecht prinesie \u00fadaje od pacientov zaraden\u00fdch do ACM
\nregister na identifik\u00e1ciu skup\u00edn pacientov vyu\u017e\u00edvaj\u00facich umel\u00fa inteligenciu. Identifikovan\u00e9
\nklastre bud\u00fa validovan\u00e9 medzi jednotliv\u00fdmi modalitami (EKG, zobrazovanie srdca, biovzorky). V
\nokrem toho bude UMC Utrecht vykon\u00e1va\u0165 pokro\u010dil\u00e9 omick\u00e9 \u0161t\u00fadie na vzork\u00e1ch tkaniva ACM,
\nvr\u00e1tane transkriptomiky jednotliv\u00fdch jadier, zachyt\u00e1vania in situ, sekvenovania RNA a
\nproteomiky. Tieto v\u00fdsledky sa n\u00e1sledne premietnu do in\u00fdch pracovn\u00fdch bal\u00edkov s cie\u013eom identifikova\u0165
\nmo\u017en\u00e9 drogov\u00e9 ciele.<\/p>\n

\n<\/div>

<\/div>
webov\u00e1 str\u00e1nka<\/span><\/a><\/div>
<\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>
<\/div>
\"UMC<\/span><\/div><\/div><\/div><\/div><\/div><\/div>
<\/div><\/div><\/div><\/div><\/div><\/div>
\"Lutech\"<\/span><\/div>
<\/div><\/div><\/div><\/div>

Lutech Advanced Solutions SPA (LUTECH)<\/span><\/span><\/h3><\/header>
<\/div>
<\/div>
<\/p>\n

Lutech Advanced Solutions vynik\u00e1 ako popredn\u00fd poskytovate\u013e technologick\u00fdch rie\u0161en\u00ed, zn\u00e1my svojimi inovat\u00edvnymi a pokro\u010dil\u00fdmi IT slu\u017ebami. S osobitn\u00fdm d\u00f4razom na \u0161pi\u010dkov\u00e9 rie\u0161enia poskytuje spolo\u010dnos\u0165 \u0161irok\u00e9 spektrum slu\u017eieb od digit\u00e1lnej transform\u00e1cie a kybernetickej bezpe\u010dnosti a\u017e po cloud computing a anal\u00fdzu \u00fadajov. V r\u00e1mci projektu IMPACT sa spolo\u010dnos\u0165 Lutech zaviazala zlep\u0161i\u0165 fenotypiz\u00e1ciu a klinick\u00fa u\u017eito\u010dnos\u0165 predklinick\u00fdch modelov. Cie\u013eom je zv\u00fd\u0161i\u0165 predv\u00eddate\u013enos\u0165 terapeutick\u00fdch pr\u00edstupov v klinick\u00fdch \u0161t\u00fadi\u00e1ch a mana\u017emente chor\u00f4b. Okrem toho sa Lutech akt\u00edvne podie\u013ea na v\u00fdvoji a charakteriz\u00e1cii robustn\u00fdch predklinick\u00fdch modelov, \u010d\u00edm prispieva k celkov\u00e9mu pokroku v\u00fdskumn\u00fdch metod\u00edk a v\u00fdsledkov.<\/p>\n

\n<\/div>

<\/div>
webov\u00e1 str\u00e1nka<\/span><\/a><\/div>
<\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/section>
<\/div><\/div>
<\/div><\/div><\/div><\/section><\/p>","protected":false},"excerpt":{"rendered":"","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-2918","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/impact-acmproject.eu\/sk\/wp-json\/wp\/v2\/pages\/2918","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/impact-acmproject.eu\/sk\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/impact-acmproject.eu\/sk\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/impact-acmproject.eu\/sk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/impact-acmproject.eu\/sk\/wp-json\/wp\/v2\/comments?post=2918"}],"version-history":[{"count":32,"href":"https:\/\/impact-acmproject.eu\/sk\/wp-json\/wp\/v2\/pages\/2918\/revisions"}],"predecessor-version":[{"id":4057,"href":"https:\/\/impact-acmproject.eu\/sk\/wp-json\/wp\/v2\/pages\/2918\/revisions\/4057"}],"wp:attachment":[{"href":"https:\/\/impact-acmproject.eu\/sk\/wp-json\/wp\/v2\/media?parent=2918"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}